All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Immune Augmentation of Single Contact Hepatitis B Vaccine by Using PLGA Microspheres as an Adjuvant

Author(s): SM Sivakumar2, N Sukumaran2, R Murugesan2, TS Shanmugarajan2, J Anbu2, L Sivakumar2, B Anilbabu2, G Srinivasarao2, V Ravichandran2
2 Vel’s College of Pharmacy, Pallavaram, Chennai-600 117, India 2 Sri Paramakalyani Centre for Environmental Sciences, Maonmaniam Sundaranar University, Alwarkurichi-627 412, India 2Sophisticated Analytical Instrument Facility, Indian Institute of Technology, Chennai-600 036, India

Correspondence Address:
S M Sivakumar Vel’s College of Pharmacy, Pallavaram, Chennai-600 117 India E-mail: [email protected]


The present study was aimed to replace the alum type adjuvant for hepatitis B vaccine. The hepatitis B vaccine was encapsulated in poly (DL-lactide-co-glycolide) microspheres by solvent evaporation technique. The formulated microspheres were characterized in terms of morphology, particle size analysis, in vitro release study and in vivo immune response in male Wistar rats. The FT IR spectrum illustrates the characteristics bands of poly (DL-lactide-co-glycolide) microspheres and hepatitis B vaccine at 1750 cm -1 and 1650 cm -1 , respectively. The hepatitis B vaccine loaded poly (DL-lactide-co-glycolide) microspheres were able to release antigens till day 42. Significant enhancement of specific antibodies to HBsAg was produced till day 90 after a single administration of HBsAg encapsulated poly (DL-lactide-co-glycolide) microspheres. However, the conventional alum adsorbed hepatitis B vaccine was not found to produce any significant specific antibody levels till day 90 after a single dose. The results showed that poly (DL-lactide-co-glycolide) microspheres show potential as an adjuvant for hepatitis B vaccine.



Share this